Clinical Trial Update: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

This clinical trial update reports phase 2 results for NS-0200 versus placebo assessing hepatic fat reduction in non-alcoholic fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• NS-0200

Snippet

Sponsor: NuSirt Biopharma | Conditions: NAFLD | Phase 2 | Status: COMPLETED | Results posted: 2018-05-02